Hikma delivers revenue growth of 21% and EPS up 24% for 2012

13 March 2013

Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) has reported preliminary results for 2012, showing that group revenues increased 20.8% to $1.11 billion, with organic revenue growth of 5.2%. Profit attributable to shareholders was up 25.2% to $100.3 million. On an adjusted basis, profit attributable to shareholders up 19.4% to $120.5 million.

Earnings before interest, taxes, depreciation and amortization (EBITDA for full-year 2012 came in at $225.2, a leap of 35.9%. Earnings per share rose 23.8% to $0,511. The figures were ahead of consensus forecasts but in line with those of analysts at Panmure Gordon

Branded revenue growth of 19.7% to $528.9 million reflects strong demand across the Middle East and North Africa (MENA) markets, with organic growth of 11.3%, said Hikma, noting that branded adjusted operating profit increased by 17.6%, with an adjusted operating margin of 23.4%

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK